The Phase 1/2a trial of ARO-MAPT aims to enroll 112 total participants, expanding from healthy volunteers into patients with early Alzheimer's disease receiving up to five subcutaneous injections, with further data updates expected in 2027.

From the articleArrowhead reports positive interim data for Alzheimer’s drug By Investing.comAlso in Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop, Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit